MarketCap
Facebook
X
TelegramAphria Inc. Langfristige Verbindlichkeiten 2011-2025 | APHA
Langfristige Verbindlichkeiten Jährlich Aphria Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 490 M | 570 M | 96.6 M | 31.8 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 570 M | 31.8 M | 297 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
AC Immune SA
ACIU
|
9.24 M | $ 2.8 | 2.19 % | $ 229 M |  Schweiz |
 |
ADiTx Therapeutics
ADTX
|
858 K | $ 2.49 | -11.39 % | $ 32.8 K |  USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Abeona Therapeutics
ABEO
|
6.69 M | $ 4.59 | -4.08 % | $ 98.1 M | USA |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
2.42 B | $ 12.12 | -1.58 % | $ 3.74 B | USA |
 |
Axcella Health
AXLA
|
26.4 M | - | -16.42 % | $ 249 M | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
14 M | $ 5.37 | -20.68 % | $ 194 M | USA |
 |
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | USA |
 |
argenx SE
ARGX
|
226 M | $ 919.62 | 2.76 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
101 M | $ 203.0 | -3.72 % | $ 5 B |  Danmark |
 |
Achieve Life Sciences
ACHV
|
159 K | $ 4.64 | -0.32 % | $ 92 M | USA |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
374 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.36 | 2.73 % | $ 8.08 B |  Australia |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
8.22 M | $ 3.29 | -1.5 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
635 M | $ 54.27 | -1.38 % | $ 10.3 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Baudax Bio
BXRX
|
65.4 M | - | 0.59 % | $ 63 K | USA |
 |
AbbVie
ABBV
|
81.7 B | $ 224.99 | -0.01 % | $ 398 B | USA |
 |
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | USA |
 |
CymaBay Therapeutics
CBAY
|
1.26 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 96.22 | -1.21 % | $ 27.2 B |  Germany |
 |
Codiak BioSciences
CDAK
|
119 M | - | -55.98 % | $ 2.15 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
263 M | $ 18.75 | -0.48 % | $ 2.76 B | USA |
 |
Avid Bioservices
CDMO
|
21.2 M | - | - | $ 789 M | USA |
 |
BioXcel Therapeutics
BTAI
|
1.4 M | $ 1.92 | -7.01 % | $ 4.87 M | USA |
 |
Biogen
BIIB
|
9.03 B | $ 179.76 | 1.11 % | $ 26.2 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
4.4 M | - | - | $ 7.29 B | USA |
 |
ContraFect Corporation
CFRX
|
9.41 M | - | -5.16 % | $ 5.39 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Beam Therapeutics
BEAM
|
26 M | $ 23.52 | -2.22 % | $ 1.94 B | USA |
 |
AbCellera Biologics
ABCL
|
228 M | $ 3.45 | -0.72 % | $ 1.02 B | Canada |
 |
Cabaletta Bio
CABA
|
43.9 M | $ 2.37 | -2.67 % | $ 2.77 M | USA |
 |
Clearside Biomedical
CLSD
|
4.72 M | - | - | $ 25.3 M | USA |
 |
Celsion Corporation
CLSN
|
12.2 M | - | -6.63 % | $ 13.9 M | USA |
 |
Clovis Oncology
CLVS
|
579 M | - | -7.23 % | $ 13 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Chimerix
CMRX
|
196 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
17.9 M | - | - | $ 401 M | USA |